Skip to content
Showing 21 - 30 of 1443 results.
“Approval of esketamine is important for patients because other options like transcranial magnetic stimulation work more poorly in medication-resistant depression,” writes Dr. J. John Mann.
“This is undeniably a major advance,” said Dr. Jeffrey Lieberman. But he cautioned much is still unknown about the drug, particularly regarding its long-term use.
The FDA is set to approve SPRAVATOTM, an esketamine nasal spray that could help certain patients with severe depression. Dr. Drew Ramsey explains.
The test could give parents false hope about quick answers for their child’s diagnosis — and, in doing so, prolong their path to the right answer, Dr. Jeremy Veenstra-VanderWeele says.
"I expect that clinicians will change their practices by prescribing fewer benzodiazepines and more antidepressants for people with schizophrenia," Dr. T. Scott Stroup said.
Dr. Evelyn Attia talks about the Columbia Center for Eating Disorders' annual trip to Albany, NY, on behalf of the Comprehensive Care Centers for Eating Disorders (CCCED).
“When the child has not made academic progress despite accommodations, he or she can develop other challenges that negatively affect their functioning at home and at school,” says Dr. Meghan Tomb.
Dr. Jeremy Veenstra-VanderWeele is studying autism and OCD using rodents that show repetitive behaviors.
Dr. John Mann and colleagues followed 663 young adults who were at high risk for suicidal behavior because their parents had been diagnosed with mood disorders.
Dr. Sidney Hankerson is the inaugural co-director of the Zuckerman Institute Community Wellness Center at Columbia’s Manhattanville campus.